Ivermectin, Fenbendazole and Mebendazole for Stage 4 Prostate Cancer: A Case Series of 40 Patients (May 2026 Update) (2025)

Other · One Day MD (onedaymd.substack.com) · August 9, 2025

One Day MD (onedaymd.substack.com), 2025-08-09: Compilation of stage 4 prostate cancer testimonials, opened with a case of an 84-year-old Florida man whose PSA reportedly fell from 425 to 2.2 after four months on ivermectin and fenbendazole.

This article compiles and systematically presents anecdotal case reports and preliminary clinical data on the use of ivermectin and benzimidazoles (fenbendazole and mebendazole) in patients with stage 4 prostate cancers

One Day MD (onedaymd.substack.com), 2025-08-09: Compilation of stage 4 prostate cancer testimonials, opened with a case of an 84-year-old Florida man whose PSA reportedly fell from 425 to 2.2 after four months on ivermectin and fenbendazole. C4. Study type: testimonial compilation; n=40 by the May 2026 update (22 in the original 2025 edition). Country: cases are international; the lead case is from Florida, USA. Doses: per testimonial, not tabulated. Other treatments: mixed; the lead case is described as self-directed. Outcome: patient-reported PSA and alkaline phosphatase changes ('PSA 425 to 2.2, ALK Phos 3655 to 209'). PATIENT-REPORTED, NOT INDEPENDENTLY VERIFIED. The compiler states elsewhere on the page an estimate that 'over 100,000 cancer patients are currently using Ivermectin, Fenbendazole, Mebendazole or some combination' – an estimate, not a count. No funding or conflict disclosure on the page. Also filed as IVD-45 (claims C4, C7).